$ORCL — AVOID 📊 | 6 MONTHS THESIS

$ORCL — AVOID 📊 | 6 MONTHS THESIS 🧭 Conviction: MED 🎯 FQ4 FY2027 (ends May) | reported Jun 10 | Rev $17.2B | EPS $1.79 vs $1.58 🟢 | Margin 55.8% 💡 Consensus appears to be extrapolating the strong quarter, but the current P/E of 31.6x (84th percentile historically) embeds overly optimistic growth assumptions. A normalization of the multiple toward the median 19.3x would cause significant downside, even if earnings hold up. 🏢 Business Quality: 7/10 📊 Valuation: rich — trailing P/E 20.7x on adjusted $7.16 EPS is above historical median (19.3x) and peer base (18.7x). 🔮 Catalyst: Next quarterly earnings ⚖️ Avoid ORCL as a long at $148.53 — rich valuation, poor 0.8:1 reward/risk, and elevated expectations create an unfavorable setup; consider only if it pulls back to $130–$135 where the risk/reward would improve.

🧭 Conviction: MED